Earnings Feed
Start Free
Home/Filings/4/0000897069-24-001992
4//SEC Filing

Dearborn Dan 4

Accession 0000897069-24-001992

CIK 0001498382other
View on SEC.govCompany Profile

Filed

Oct 21, 8:00 PM ET

Accepted

Oct 22, 8:01 PM ET

Size

14.6 KB

Accession

0000897069-24-001992

Insider Transaction Report

Form 4
Period: 2024-10-18
Kintara Therapeutics, Inc.KTRA
Dearborn Dan
Chief Financial Officer
Transactions
  • Award

    Options (Right to Buy)

    2024-10-18+68,438→ 68,438 total
    Exercise: $2.24From: 2024-10-18Exp: 2026-12-20→ Common Stock (68,438 underlying)
  • Award

    Options (Right to Buy)

    2024-10-18+232,570→ 232,570 total
    Exercise: $3.69Exp: 2032-11-15→ Common Stock (232,570 underlying)
  • Award

    Options (Right to Buy)

    2024-10-18+33,991→ 33,991 total
    Exercise: $2.24From: 2024-10-18Exp: 2026-01-17→ Common Stock (33,991 underlying)
  • Award

    Options (Right to Buy)

    2024-10-18+66,658→ 66,658 total
    Exercise: $4.14Exp: 2034-02-28→ Common Stock (66,658 underlying)
  • Award

    Options (Right to Buy)

    2024-10-18+15,744→ 15,744 total
    Exercise: $3.69Exp: 2033-04-07→ Common Stock (15,744 underlying)
Footnotes (4)
  • [F1]Securities issued upon closing of the transactions contemplated by the Agreement and Plan of Merger, dated as of April 2, 2024 (the "Merger Agreement"), among the Issuer (fka "Kintara Therapeutics, Inc."), Kayak Mergeco, Inc., a Delaware corporation and wholly owned subsidiary of Issuer ("Merger Sub"), and TuHURA Biosciences, Inc., a Delaware corporation ("Private TuHURA"). Under the terms of the Merger Agreement, on October 18, 2024, Merger Sub merged with and into Private TuHURA (the "Merger") with Private TuHURA surviving the Merger as a wholly owned subsidiary of the Issuer. Upon the closing of the Merger, securities of Private TuHURA were converted into the right to receive securities of the Issuer as set forth in the Merger Agreement. The Issuer subsequently changed its name to "TuHURA Biosciences, Inc."
  • [F2]One-third of the stock options become exercisable on the first, second, and third anniversary of November 15, 2023.
  • [F3]One-third of the stock options become exercisable on the first, second, and third anniversary of April 7, 2023.
  • [F4]One-third of the stock options become exercisable on the first, second, and third anniversary of February 28, 2024.

Documents

1 file

Issuer

Kintara Therapeutics, Inc.

CIK 0001498382

→
Entity typeother

Related Parties

1
  • filerCIK 0001975443

Filing Metadata

Form type
4
Filed
Oct 21, 8:00 PM ET
Accepted
Oct 22, 8:01 PM ET
Size
14.6 KB
View on SEC.gov